| Literature DB >> 21170717 |
Jonathan Bergman1, Arlene Fink, Lorna Kwan, Sally Maliski, Mark S Litwin.
Abstract
PURPOSE: Despite the positive influence of spiritual coping on the acceptance of a cancer diagnosis, higher spirituality is associated with receipt of more high intensity care at the end of life. The purpose of our study was to assess the association between spirituality and type of end-of-life care received by disadvantaged men with prostate cancer.Entities:
Mesh:
Year: 2010 PMID: 21170717 PMCID: PMC3024492 DOI: 10.1007/s00345-010-0610-y
Source DB: PubMed Journal: World J Urol ISSN: 0724-4983 Impact factor: 4.226
Demographic and clinical characteristics of the study sample (n = 35)
| Characteristic | Number of patients (%) |
|---|---|
| Age (years ± SD) | |
| Mean age at IMPACT enrollment | 62.7 ± 9.8 |
| Mean age at death | 64.2 ± 9.7 |
| Average length of IMPACT enrollment at time of death (months ± SD) | 18.4 ± 13.4 |
| Ethnicity | |
| White | 6 (17.1) |
| African American | 5 (14.3) |
| Hispanic | 24 (68.6) |
| Job status | |
| Employed | 17 (48.6) |
| Unemployed | 18 (51.4) |
| Number of dependents | |
| 0 | 13 (37.1) |
| ≥1 | 22 (62.9) |
| Partnership status | |
| In relationship | 25 (71.4) |
| Not in relationship | 10 (28.6) |
| Region of residence | |
| Northern California | 11 (31.4) |
| Southern California | 24 (68.6) |
| Pre-treatment PSA (1 missing) | |
| <4 | 3 (8.8) |
| 4–10 | 4 (11.8) |
| ≥10 | 27 (79.4) |
| Biopsy Gleason score | |
| ≤6 | 5 (14.3) |
| 7 | 11 (31.4) |
| ≥8 | 19 (54.3) |
| Clinical stage | |
| T1 (localized) | 13 (37.1) |
| T2 (localized) | 12 (34.3) |
| T3 (locoregional) | 5 (14.3) |
| T4 (metastatic) | 5 (14.3) |
| D’amico risk stratification | |
| Low risk | 2 (5.7) |
| Intermediate risk | 2 (5.7) |
| High risk | 31 (88.6) |
| Treatment within IMPACT | |
| Radical prostatectomy | 3 (8.6) |
| Radiation therapy | 1 (2.9) |
| Radiation therapy + androgen deprivation therapy | 4 (11.4) |
| Androgen deprivation monotherapy | 26 (74.3) |
| Active surveillance | 1 (2.9) |
| End-of-life care receiveda | |
| Hospice | 10 (28.6) |
| Zolendroic acid | 16 (45.7) |
| Chemotherapy | 22 (62.9) |
| Palliative radiation therapy | 12 (34.3) |
| PSA closest to date of death (1 missing) | |
| ≤4 | 6 (17.7) |
| 4–10 | 3 (8.8) |
| ≥10 | 25 (73.5) |
| Number of prostate cancer-related emergency room visits | |
| 0 | 13 (37.1) |
| 1 | 12 (34.3) |
| ≥2 | 10 (28.6) |
| Evidence of metastases at presentation to IMPACT | |
| Cause of death | 25 (71.4) |
| Prostate cancer | 26 (74.3) |
| Other | 9 (25.7) |
aTypes of end-of-life care were not mutually exclusive and could therefore sum more than 100%
Bivariate analysis of demographic and clinical characteristics by spirituality scores (n = 35)
| Characteristic | Number of patients (%) | ||
|---|---|---|---|
| Low FACIT-Sp <27 ( | High FACIT-Sp ≥27 ( |
| |
| Age (years ± SD) | |||
| Mean age at IMPACT enrollment | 61 ± 9 | 63 ± 10 | 0.65 |
| Mean age at death | 63 ± 8 | 65 ± 10 | 0.60 |
| Ethnicity | |||
| White | 3 (38) | 3 (11) | 0.17 |
| African American | 0 (0) | 5 (19) | |
| Hispanic | 5 (62) | 19 (70) | |
| Job status | |||
| Employed | 2 (25) | 15 (56) | 0.23 |
| Unemployed | 6 (75) | 12 (44) | |
| Number of dependents | |||
| 0 | 4 (50) | 9 (33) | 0.43 |
| ≥1 | 4 (50) | 18 (67) | |
| Partnership status | |||
| In relationship | 3 (38) | 22 (81) | 0.03 |
| Not in relationship | 5 (62) | 5 (19) | |
| Region of residence | |||
| Northern California | 2 (25) | 9 (33) | 1.0 |
| Southern California | 6 (75) | 18 (67) | |
| Pre-treatment PSA | |||
| ≤4 | 1 (13) | 2 (8) | 0.61 |
| 4–10 | 0 (0) | 4 (15) | |
| ≥10 | 7 (87) | 20 (77) | |
| Biopsy Gleason score | |||
| ≤6 | 3 (38) | 2 (7) | 0.06 |
| 7 | 3 (38) | 8 (30) | |
| ≥8 | 2 (25) | 17 (67) | |
| Clinical stage | |||
| T1 (localized) | 3 (38) | 10 (37) | 0.56 |
| T2 (localized) | 3 (38) | 9 (33) | |
| T3 (locoregional) | 0 (0) | 5 (19) | |
| T4 (metastatic) | 2 (25) | 3 (11) | |
| D’amico risk stratification | |||
| Low risk | 1 (13) | 1 (4) | 0.22 |
| Intermediate risk | 1 (13) | 1 (4) | |
| High risk | 6 (75) | 25 (93) | |
| Treatment within IMPACT | |||
| Radical prostatectomy | 1 (13) | 2 (7) | 0.33 |
| Radiation therapy | 0 (0) | 1 (4) | |
| Radiation therapy + androgen deprivation | 0 (0) | 4 (15) | |
| Androgen deprivation monotherapy | 6 (75) | 20 (74) | |
| Active surveillance | 1 (13) | 0 (0) | |
| PSA closest to date of death | |||
| ≤4 | 2 (25) | 4 (15) | 0.52 |
| 4–10 | 1 (13) | 2 (8) | |
| ≥10 | 5 (63) | 20 (77) | |
| Number of emergency room visits | |||
| 0 | 2 (25) | 11 (41) | 0.61 |
| 1 | 4 (50) | 8 (30) | |
| ≥2 | 2 (25) | 8 (30) | |
| Evidence of metastases at presentation to IMPACT | 5 (63) | 20 (74) | 0.66 |
| Cause of death | |||
| Prostate cancer | 4 (50) | 22 (81) | 0.16 |
| Other | 4 (50) | 5 (19) | |
End-of-life care received, stratified by spirituality scores (n = 35)
| Number of patients (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospice | Zolendroic acid | Chemotherapy | Palliative radiation | |||||||||
| Yes | No |
| Yes | No |
| Yes | No |
| Yes | No |
| |
| Spirituality | ||||||||||||
| Low (<27) | 1 (10) | 7 (28) | 0.39 | 4 (25) | 4 (21) | 1.0 | 5 (23) | 3 (23) | 1.0 | 2 (17) | 6 (26) | 0.69 |
| High (≥27) | 9 (90) | 18 (72) | 12 (75) | 25 (79) | 17 (77) | 10 (77) | 10 (83) | 17 (74) | ||||
| Peace subscale | ||||||||||||
| Low (<18) | 1 (10) | 6 (24) | 0.64 | 4 (25) | 3 (16) | 0.68 | 5 (23) | 2 (15) | 0.69 | 2 (17) | 5 (22) | 1.0 |
| High (≥18) | 9 (90) | 19 (76) | 12 (75) | 16 (84) | 17 (77) | 11 (85) | 10 (83) | 18 (78) | ||||
| Faith subscale | ||||||||||||
| Low (<8) | 1 (10) | 6 (24) | 0.64 | 4 (25) | 3 (16) | 0.68 | 5 (23) | 2 (15) | 0.69 | 2 (17) | 5 (22) | 1.0 |
| High (≥8) | 9 (90) | 19 (76) | 12 (75) | 16 (84) | 17 (77) | 11 (85) | 10 (83) | 18 (78) | ||||